ASH 2019 | Mosunetuzumab individualized risk mitigation approach for NHL
Catherine Diefenbach
• 7 Dec 2019
Neurologic toxicities have resulted in restrictions in driving and other activities for patients receiving CD19-targeting therapies. Mosunetuzumab is a CD3/CD20 bispecific antibody, which may have milder neurologic toxicities than CD19-targeted therapies. Here, Catherine Diefenbach, MD, Perlmutter Cancer Center at NYU Langone Health, New York, NY, discusses the results from a systematic review of neurologic adverse events in non-Hodgkin lymophoma patients treated with this agent, where an individualized risk mitigation approach for driving allowed for a more patient-centric strategy. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
